Dyslipidemia is one of the major modifiable risk factors for cardiovascular disease (CVD). While new evidence demonstrates betters outcomes for patients and increases our knowledge of dyslipidemia management, the ever-changing landscape of lipid treatment poses challenges for care providers, related to appropriate risk assessment, treatment, and surveillance options for at-risk populations. In this presentation, the current CCS Dyslipidemia Guideline Committee will present on the following topics:
(i) In primary prevention, what ancillary approaches can physicians use to counsel individuals toward lifestyle change and identify individuals for earlier treatment? (vascular age, lifetime risk, benefit approach).
(ii) In adults already receiving or intolerant to statins, what is the role of other lipid-modulating drugs compared with placebo reduce CVD events?
(iii) In secondary prevention, what is the most appropriate lipid/lipoprotein threshold for intensification of therapy?
This session will be focused on case-based discussions of these topics and is intended to engage the audience in an informal debate/discussion and inform the guideline committee of the opinions of practitioners across the country.